According to a recent LinkedIn post from Beacon Therapeutics, Chief Scientific Officer Abraham Scaria is scheduled to speak at the 9th Annual Gene Therapy Development Summit in Boston on March 25. The talk will address gene therapy for dry age-related macular degeneration using AAV vectors with a focus on improving durability and patient compliance.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests Beacon is positioning its scientific leadership within the ophthalmology and gene therapy communities, potentially strengthening visibility among partners, peers, and investors. Increased exposure around indications such as dry AMD and X-linked retinitis pigmentosa may support the company’s profile in a competitive retinal disease pipeline, which could be relevant for future funding and collaboration opportunities.